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The catalytic properties and sensitivity to different inhibitors have been determined for the reverse transcriptase (RT) of
group O human immunodeficiency virus type 1 (HIV-1). The RT-coding region was cloned from a new HIV-1 group O isolate
from Spain, expressed in Escherichia coli, and purified by affinity chromatography. This new RT showed 79% amino acid
sequence identity with the corresponding enzyme of group M subtype B strain BH10. The two enzymes showed very similar
kinetics of RNA-dependent DNA polymerization using homopolymeric template-primers and RNase H specific activity.
Inhibitor sensitivity to ddTTP and 3*-azido-2*,3*-dideoxythymidine triphosphate (AZTTP) was also similar for both enzymes.
However, the two enzymes differed dramatically in their sensitivity to several inhibitors. While the RT of the BH10 isolate
was sensitive to nevirapine and loviride (IC50 ranged from 0.16 to 8.2 mM, depending on the substrates used), the enzyme
of the Spanish HIV-1 group O isolate showed high-level resistance to those compounds (IC50  200 mM). The amino acid
sequence of the RT of group O HIV-1 contains three amino acids (Cys-181, Glu-179, and Gly-98), which are found in group
M subtype B strains resistant to nonnucleoside RT inhibitors. The recombinant group O HIV-1 RT should be useful for
studies aimed at discovering and designing drugs directed toward group O isolates of HIV-1. q 1997 Academic Press
INTRODUCTION al., 1996; Peeters et al., 1997), as well as in Europe (Lous-
sert-Ajaka et al., 1995; Hampl et al., 1995; Soriano et al.,
Human immunodeficiency virus type 1 (HIV-1) displays 1996), and the U.S. (Gould et al., 1996). In one case, HIV-
a high degree of genetic variability in vivo. Two major 1 group O has been isolated from a Caucasian woman
groups have been defined to classify the circulating HIV-
living in France with no known ties to Africa (Charneau et
1 strains: Group M (main) and Group O (outlier). Group M
al., 1994). All these data suggest that this group of HIV-1
can be further subdivided into at least 10 different sub-
has begun to spread to many areas of the world from its
types (A–J), which are widely distributed around the world.
likely original source in Central Africa.
Phylogenetic analysis of the env region of these subtypes
Analysis of group O strains shows that they are highlyshows that they are approximately equidistant from one
divergent from other subtypes and are almost as close toanother, producing a ‘‘star’’ phylogeny. The first HIV-1 of
HIV-2 as to HIV-1. Conventional screening tests (Westerngroup O (ANT70) was isolated in 1987, from two Cameroo-
blot, ELISA, or polymerase chain reaction) designed tonians living in Belgium, and a partial nucleotide sequence
detect HIV-1 or HIV-2 in infected individuals can fail toof the virus was reported 3 years later (De Leys et al.,
detect infection by HIV-1 group O viruses (Loussert-Ajaka1990). Recent epidemiological data revealed that HIV-1
et al., 1994; Schable et al., 1994). The diversity of groupgroup O infection is widely distributed in Cameroon and
O strains is most remarkable at the V3 loop region ofprobably in the neighboring countries Gabon and Nigeria
gp120. The tip of the loop of the characterized group O(Mulanga Kabeya et al., 1995; Delaporte et al., 1996;
strains does not contain the GPG motif, which is presentMaucle`re et al., 1997; Peeters et al., 1997). Its prevalence
in most group M isolates (Blouin et al., 1996). Instead,has been estimated to be around 6 to 8% among HIV-
the V3 loop of group O HIV-1 strains bears the motifsinfected people in urban areas of Cameroon (Gu¨rtler et
GPM or GPL (De Leys et al., 1990; Charneau et al., 1994;al., 1994; Maucle`re et al., 1997). In addition, HIV-1 group
Gu¨rtler et al., 1994; Loussert-Ajaka et al., 1995; Korber etO infection has been identified in other countries of West
al., 1996; Mas et al., 1996; Maucle`re et al., 1997). Unlikeand South East Africa (Heyndrickx et al., 1996; Songok et
HIV-1 group M strains, group O strains as well as other
primate immunodeficiency viruses do not require
1 Present address: Division of Infectious Diseases, Biomedical Re- cyclophilin A for replication (Braaten et al., 1996). Taken
search Building, Case Western Reserve University, 10900 Euclid Ave., together, these observations suggest that both HIV-1Cleveland, OH 44106-4984.
groups were transmitted to humans from other primate2 To whom correspondence and reprint requests should be ad-
dressed. Fax: 34-1-3974799. E-mail: edomingo@trasto.cbm.uam.es. species in two separate events.
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HIV-1 group O infection poses a potential public health able kit (Geneclean II kit, Bio101, Vista, CA). Direct se-
quencing of the PCR-amplified DNA was performedrisk, and successful antiviral strategies must be able to
cope with the observed differences between group O using the femtomole method (Promega) followed by treat-
ment of the reaction mixture with terminal deoxynucleoti-and group M viruses. The reverse transcriptase is an
important target for therapeutic intervention. Studies on dyl transferase (Quin˜ones-Mateu et al., 1996). Primers
used in the sequencing reactions are given in Table 1.the phenotypic sensitivity to antiretroviral drugs per-
formed using HIV-1 group O isolates recovered from in- The purified DNA obtained from the nested PCR was
cleaved with NcoI and EcoRI, and cloned into the expres-fected individuals revealed that group O viruses were
sensitive to the reverse transcriptase inhibitors AZT (zi- sion vector pRT6. This vector derives from p66(RT), a pUC
plasmid that when introduced in E. coli induces the synthe-dovudine), ddI (didanosine), and ddC (zalcitabine) and to
the protease inhibitor saquinavir (Descamps et al., 1995). sis of large quantities of the 66-kDa subunit of HIV-1 RT
(Hizi et al., 1988). To facilitate cloning, we introduced anHowever, they were resistant to the nonnucleoside re-
verse transcriptase inhibitors delavirdine and TIBO EcoRI site at the 3* end of the RT coding region of p66(RT).
For such a purpose, 20 pmol of oligonucleotides Eco35R82913 (Descamps et al., 1995). Here, we report on the
characterization of the enzymatic properties and inhibitor and Eco53 (Table 1) were phosphorylated with T4 poly-
nucleotide kinase (Boehringer) in the presence of 1 mMsensitivity of a recombinant HIV-1 group O reverse tran-
scriptase that has been expressed in Escherichia coli ATP. Equal amounts of each primer were then mixed, incu-
bated at 957 for 3 min and slowly cooled at room tempera-and bears the amino acid sequence derived from an HIV-
1 group O strain previously isolated in Spain (Soriano et ture, to form a duplex with two cohesive ends. These over-
hangs are compatible with the cohesive ends obtainedal., 1996).
after digestion of p66(RT) with SalI and HindIII. Ligations
and transformations were done following standard proto-MATERIALS AND METHODS
cols. After cloning the cleaved product of the nested PCR in
Viral isolates and preparation of DNA template plasmid pRT6, the nucleotide sequence of selected clones
harboring the coding region of the 66-kDa subunit of thePeripheral blood mononuclear cells (PBMCs) from a
RT was determined and compared to the sequence ob-35-year-old man infected with group O HIV-1 (ESP1 iso-
tained from the PCR product.late) (Soriano et al., 1996) were collected at the Centro
The coding region of the 51-kDa subunit of the HIV-1de Investigaciones ClıB nicas, Instituto de Salud Carlos III
RT was cloned in the expression vector pTrcHisB (In-(Madrid, Spain) in April and September 1995. Proviral
vitrogen Corp.). For such a purpose, a DNA fragmentDNA was extracted directly from uncultured PBMCs as
containing the nucleotide sequence of p51 was synthe-previously described (Quin˜ones-Mateu et al., 1995).
sized by PCR using primers RTO7 and RTO8 (Table 1).
PCR was done as described above. A plasmid derivedPolymerase chain reaction (PCR) amplification and
from pRT6 and containing the coding region of the 66-plasmid construction
kDa subunit was used as template DNA. The amplified
DNA was analyzed on an agarose gel, purified, andGenomic regions encoding the 66-kDa subunit of the
RT were amplified using a ‘‘nested’’ polymerase chain cleaved with NheI and EcoRI. Then, it was cloned into
the plasmid pTrcHisB, previously digested with both en-reaction and specific oligonucleotide primers (Table 1).
PCR amplifications were all done in 10 mM Tris–HCl (pH zymes.
8.3), 50 mM KCl, 1.5 mM MgCl2 , 0.01% gelatin, a 0.2
mM concentration of each of the four deoxynucleotide Protein expression and purification
triphosphates, 200 ng of each primer, and 1 unit of Taq
polymerase (Perkin–Elmer–Cetus, Norwalk, CT) in a vol- Purification of recombinant RTs was carried out after
independent expression of their subunits, by following aume of 100 ml. One microgram of template DNA and
primers RTO1 and RTO2 (Table 1) were used in the first previously described procedure (MartıB n-HernaB ndez et al.,
1996). The E. coli strains used in these experiments wereexternal amplification. PCR amplification was initiated
with an incubation at 947 for 5 min, followed by 3 cycles DH5a and the Epicurean TOPP cells (Stratagene). As a
consequence of the cloning scheme, the 66-kDa subunitof 947 for 1 min, 557 for 1 min, and 727 for 1 min; 32
cycles of 947 for 15 sec, 557 for 45 sec, and 727 for 1 contains two additional amino-terminal residues (Met-
Val-) which are not found in the viral RT (Hizi et al., 1988).min; and a final incubation at 727 for 10 min. Samples of
the products of the primary reaction were reamplified The 51-kDa subunit was obtained with an extension of
14 amino acid residues at its N-terminal end which in-using nested inner primers RTO3 and RTO4 (Table 1).
This amplification was done using the same conditions cludes six consecutive histidines to facilitate its purifica-
tion by metal chelate affinity chromatography (LeGrice etas for the external PCR. The products, including negative
controls (without DNA), were examined by agarose gel al., 1991). The purity of the enzyme was assessed by
sodium dodecyl sulfate–polyacrylamide gel electropho-electrophoresis and purified using a commercially avail-
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TABLE 1
Synthetic Oligonucleotides Used as Primers for Polymerase Chain Reaction (PCR), Nucleotide Sequencing, and Plasmid Modification
Oligonucleotide Sequence (5* r 3*) Orientation Position a
RTO1 GGAACAGTATTGGTGGGACC Sense 2524
RTO2 TTCACTAGCTAGTGCTTTCC Antisense 4340
RTO3 GTACACCCATGGTCCCTATAAGCCCCATAGCCC Sense 2591
RTO4 GGTCTATTCGAATTCATCACAGGACTCTTCTAATATC Antisense 4267
RTO5 TAGGTATCCCACATCCGGGG Sense 2879
RTO6 TCTTTGGAATCCTGTAAGGC Antisense 4057
RTO7 GGAAGGATCCGCTAGCCCTATAAGCCCCATAGCC Sense 2605 b
RTO8 GCTCCATGAATTCAATAGGTTTCTGCCCCC Antisense 3909
RTO9 ATCAGTGGGGATTCACTACC Sense 3233
RTO10 ATTCCTGAGACACCTTCTGG Antisense 3720
Eco35 AGCTTGGGCTGCAGAATTCG — —
Eco53 TCGACGAATTCTGCAGCCCA — —
a The number given corresponds to the position of the 5* terminus of the HIV-1 ANT70 sequence as shown under GenBank Accession No. L20587
(Vanden Haesevelde et al., 1994).
b The first 15 bases of this oligonucleotide are complementary to the DNA sequence of plasmid pRT6. Position number refers to the underlined
nucleotide.
resis. RT concentrations were determined using the Bio- binding to HIV-1 RT were determined as the apparent Km
Rad protein assay. values for template-primer binding, when the concentra-
tion of dTTP was held fixed at 15 of its Km value, determined
Enzymatic assays at saturating concentrations of template-primer (Reardon
et al., 1991).DNA polymerase activity assays were carried out in
RT inhibition was studied using ddTTP (Pharmacia),50 mM Tris–HCl (pH 8.0), 20 mM NaCl, 10 mM MgCl2 ,
AZTTP (Moravek Biochemicals, Brea, CA), nevirapine,8 mM dithiothreitol, 3–5 mCi/ml [3H]dTTP or [8-3H]dGTP,
and loviride (a-anilinophenylacetamide derivative Rand 0.5–1 mM template-primer (concentration expressed
89439). Nevirapine and loviride were kindly provided toas 3*-hydroxyl primer termini). The template-primers
one of us (V.S.) by Boehringer Ingelheim Pharmaceuticalsused were poly(rA)roligo(dT)20 , poly(rA)roligo(dT)12 – 18 ,
and The Wellcome Foundation Ltd., respectively. The Kipoly(rC)roligo(dG)12–18 , and poly(dC)roligo(dG)12–18 .
values for ddTTP and AZTTP were determined in thePoly(rA)roligo(dT)20 was prepared by mixing 52 ml of 100
presence of saturating concentrations of template-mM phosphorylated oligo(dT)20 (Pharmacia), 6 ml of po-
primer, by using two different methods. First, the inhibi-ly(rA)450 (Pharmacia) at 700 A260 units/ml, and 40 ml of
tion of the DNA polymerase activity of the RT was mea-distilled water. Poly(rA)roligo(dT)12 – 18 and poly(rC)roli-
sured by varying the concentration of ddTTP or AZTTP,go(dG)12 – 18 (Pharmacia) were dissolved in distilled water
in the presenced of a fixed concentration of dNTP, asat 14.0 and 16.0 A260 units/ml, to obtain stock solutions
previously described (Fan et al., 1996). Then, apparentwith a primer concentration of 100 mM. Poly(dC)roli-
Km values measured in the presence of fixed concentra-go(dG)12 – 18 was prepared by mixing 25.4 ml of phosphory-
tions of inhibitor (at around 1–4 times the Ki obtainedlated oligo(dG)12 – 18 (400 mM) and 86 ml of poly(dC)420
using the previous method) were determined by fitting(Pharmacia) at 29.3 A260 units/ml. In all cases, the tem-
the velocity data to the Michaelis–Menten equation asplate–primer mixtures were annealed at 907 for 5 min
above. Inhibition constants were calculated from theand slowly cooled at room temperature prior to use. For
equation Km(app)  Km (1 / [I]/Ki), derived for competitivethe determination of kinetic parameters, the dTTP con-
inhibition. In the experiments carried out with nevirapinecentration was adjusted with nonradioactive nucleotide
and loviride, the IC50 values were determined with re-and ranged from 1 mM to 500 mM. Reactions (30 ml)
spect to [3H]dTTP or [8-3H]dGTP incorporation. The corre-were initiated by the addition of 0.8–3 pmol of enzyme,
sponding template-primers and dNTPs were used at 1incubated at 377 for 10–30 min, and terminated by adding
and 2 mM concentration, respectively.20 ml of 0.5 M EDTA. The amount of polymerized deoxy-
RNase H activity assays were performed in the pres-nucleotide was determined by acid insoluble precipita-
ence of MgCl2 , using [
3H]Poly(rA)rPoly(dT) as substrate,tion (MartıB n-HernaB ndez et al., 1997). Kinetic parameters
as previously described (MartıB n-HernaB ndez et al., 1997).of polymerization were calculated by fitting the data to
RNase H activity is expressed in units, where one unitthe Michaelis–Menten equation as previously described
is defined as 1 nmol of trichloroacetic acid-soluble radio-(MartıB n-HernaB ndez et al., 1996).
The dissociation constants (Kd) for poly(rA)roligo(dT)20 labeled adenylate released in 1 hr at 377.
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FIG. 1. Phylogenetic tree analysis of the RT-coding region of an HIV-1 group O nucleotide sequence from Spain (boxed), with HIV-1, HIV-2, and
simian immunodeficiency virus (SIV) isolates from the current database at Los Alamos National Laboratory. Group M and group O isolates are
indicated. GenBank accession numbers for reference sequences are as follows: U455, M62320; IBNG, L39106; MN, M17449; CAM1, D10112; RF,
M17451; BH10, M15654; ELI, K03454; Z2Z6, M22639; MAL, K03456; ANT70, L20587; MVP5180, L20571; ESP1, U97171; ROD, M15390; EHOACG,
U27200; FORTC2, M87111; CPZGAB, X52154; MM251, M19499; and STM, M83293. Neighbor-joining consensus trees were constructed using the
NEIGHBOR, SEQBOOT, and CONSENSE programs of the PHYLIP package (Felsenstein, 1989). The lengths of the branches are proportional to the
relative evolutionary distances.
RESULTS equivalent regions in ANT70 and MVP5180 were around
5 and 10%, respectively, and were similar to those found
Nucleotide and deduced amino acid sequence of the between isolates from different subtypes of group M HIV-
Spanish HIV-1 group O isolate 1 (Table 2). In contrast, the values obtained in compari-
sons between group O and group M isolates rangedThe average nucleotide sequence of the RT coding
from 31 to 34%. The primary structure derived from theregion of the Spanish isolate was compared with others
RT sequence of ESP1 is given in Fig. 2, together withobtained from representative HIV-1 strains available from
those obtained from other HIV-1 group O isolates andthe current database at Los Alamos National Laboratory.
BH10 strain. HIV-1BH10 is a representative clone of sub-A phylogenetic tree derived from this comparison is
type B, which is the prevalent subtype in Europe, Japan,shown in Fig. 1. The RT pol sequence of the Spanish
and the U.S. Pairwise comparisons between the RTs ofisolate ESP1 clusters within HIV-1 group O isolates and
group O HIV-1 isolates revealed that the number of aminois closer to the ANT70 strain. The group O strains ANT70
acid differences between them ranged from 5 to 8%. Thisand MVP5180 were isolated from symptomatic patients
value raised to 21% when the consensus sequence forfrom Cameroon. Their reported nucleotide sequences
group O viruses was compared with the sequence ofwere obtained from proviral DNA prepared from persis-
the BH10 isolate. Amino acid changes appeared to betently infected cell cultures (Vanden Haesevelde et al.,
scattered along the sequence, with a higher number of1994; Gu¨rtler et al., 1994). The cell lines used were MT4
differences in the RNase H domain than in the DNAin the case of ANT70 and HUT-78 in the case of
polymerase domain of the RT (28% versus 15%, in com-MVP5180. The sequence of the ESP1 isolate derives from
parisons between BH10 and the consensus O se-the direct amplification of proviral DNA found in the un-
quence). However, relevant differences at the DNA poly-cultured PBMCs of an infected individual. The genetic
distances between the RT coding region of ESP1 and its merase domain of the RT were detected in positions
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TABLE 2
Pairwise DNA Distance Matrices a among the Group O HIV-1 pol Sequence from Spain and Representative Sequences of Different Groups
and Subtypes of HIV-1, HIV-2, and Simian Immunodeficiency Viruses (SIV)
HIV-1
Group M HIV-2
Group O SIV
U455 BH10 ELI MAL ROD
(Subtype A) (Subtype B) (Subtype D) (subtype U) b MVP5180 ANT70 (Subtype A) CPZGAB MM251
U455 — — — — — — — 0.27 0.52
BH10 0.12 — — — — — — 0.27 0.50
ELI 0.13 0.07 — — — — — 0.27 0.50
MAL 0.12 0.11 0.11 — — — — 0.24 0.50
MVP5180 0.33 0.34 0.34 0.29 — — — 0.29 0.52
ANT70 0.35 0.35 0.34 0.31 0.10 — — 0.30 0.53
ESP1 0.36 0.35 0.34 0.32 0.10 0.05 0.51 0.29 0.53
HIV-2 ROD 0.52 0.48 0.50 0.50 0.49 0.51 — 0.51 0.51
a The values correspond to the proportion of nucleotides substituted when pairs of pol (RT-coding region) sequences were compared applying
the Kimura two-parameter model (Kimura, 1980). The genetic distances are expressed as percentage differences.
b Subtype U includes unclassified viruses. The MAL isolate has been defined as a recombinant virus of subtypes A and D.
98, 179, and 181, which are involved in resistance to strains (Fig. 2). ESP1 and ANT70 have Cys at position
181 instead of Tyr as found in MVP5180 and group M HIV-nonnucleoside reverse transcriptase inhibitors. Gly-98
and Glu-179 are found in all group O isolates, instead of 1 isolates. Despite the significant differences observed
between group O and group M HIV-1 RT sequences, theyAla and Val, respectively, which occur in group M HIV-1
FIG. 2. Alignment of amino acid sequences of RT of HIV-1 group O isolates. The consensus sequence of the group O HIV-1 RT was obtained
from the sequences of the Spanish isolate ESP1 described in this paper, ANT70 (Vanden Haesevelde et al., 1994) and MVP-5180 (Gu¨rtler et al.,
1994). The sequence of a group M HIV-1 isolate (BH10) is shown for comparison. The single-letter amino acid code is used. Dots represent identical
residues as compared with the group O HIV-1 consensus sequence. Residues involved in resistance to RT inhibitors (Domingo et al., 1997) are
marked with ˆ . The polymerase and RNase H domains (Jacobo-Molina and Arnold, 1991) are boxed. A black triangle is used to indicate the
processing site between p51 and the RNase H domain (Chattopadhyay et al., 1992).
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are more closely related to each other than to the RT of activity of the RT of the ESP1 isolate was 298.0 { 63.0
units/mg. This value was only slightly lower than the oneHIV-2. The percentage of amino acid changes observed
in the sequence derived from the RT-coding region of r e p o r t e d f o r t h e e n z y m e o f t h e B H 1 0 i s o l a t e
(MartıB n-HernaB ndez et al., 1997). Kinetic parameters forthe HIV-2ROD (Guyader et al., 1987) isolate compared with
the RTs of group O strains is around 38%. DNA polymerase activity were measured with poly(rA)r
oligo(dT)20 and dTTP and are shown in Table 3. The val-
Cloning, expression, and purification ues for dTTP incorporation (kcat and Km) were similar for
of group O HIV-1 RT the group O and the group M enzymes, although the
affinity for the RNA–DNA complex was somewhat higher
For the cloning of p66 and p51, it was assumed that the
in the case of the group O HIV-1 RT.
amino- and carboxyl-terminal ends of both subunits were
We tested the inhibitor sensitivity of the group O re-
identical to those reported for the RT of HIV-1 subtype B
combinant RT and compared it with the RT of the BH10
(DiMarzo Veronese et al., 1986; Chattopadhyay et al., 1992).
isolate. The nucleotide triphosphate analogues ddTTP
The amino acid sequence around the maturation site at
and AZTTP inhibited both enzymes in a competitive man-
the amino-terminal end of the RT was conserved in all
ner. Although the group O RT appears to be slightly more
group O viruses, as well as in BH10 (Fig. 2). At the carboxyl-
sensitive to those inhibitors, differences in their inhibition
terminal end of p66 and at the p51/RNase H cleavage sites,
constants were relatively minor (Table 4). Furthermore,
we observed three conserved substitutions: Lys-558 r Arg,
the differences between the corresponding Ki/Km ratiosIle-559 r Val, and Phe-440 r Tyr. These amino acid
for both enzymes and inhibitors were almost indistin-
changes are not expected to have a large effect in pro-
guishable. In contrast, large differences were observed
cessing by the viral protease (Poorman et al., 1991; Chou,
with nonnucleoside RT inhibitors (Table 5). Depending
1993). The region coding for the 66-kDa subunit of the ESP1
on the homopolymeric template-primer used in our assay
isolate was amplified by nested PCR using proviral DNA
conditions, the IC50 values for nevirapine and lovirideof the infected individual as template. The resulting DNA
were at least 24 to 1250 times higher with the group O
was then cloned into the pUC-derived plasmid pRT6, using
enzyme than with the group M RT.
the restriction sites NcoI and EcoRI. The obtained construct
was used for expression of p66. The nucleotide sequence
DISCUSSIONof the insert was identical to the average sequence derived
from the PCR product and used in the comparisons and
The genetic distance between the RT-coding region
phylogenetic analysis described above. The 51-kDa subunit
of the HIV-1 group O isolate (ESP1) and the previously
was obtained after cloning with appropriate primers (Table
characterized ANT70 (Vanden Haesevelde et al., 1994)
2 and Materials and Methods), using the p66 construct as
is about 5%. Their derived amino acid sequences differed
template. The nucleotide sequence of the insert was again
in 27 residues. The comparison of the primary structures
identical to that found in the template DNA. Purification of
of HIV-1 RTs of ESP1 and BH10 revealed a 79% amino
the group O HIV-1 RT was done after independent expres-
acid sequence identity between both enzymes. Forty
sion of its subunits. The 51-kDa subunit included six con-
amino acid changes are found in the polymerase domain,
secutive histidines at its amino terminal extension, to facili-
but only 16 are conservative substitutions. Site-directed
tate its purification by metal chelate affinity chromatogra-
mutagenesis studies using a subtype B clone of HIV-1
phy. The 66-kDa subunit was constitutively expressed by
RT very similar to BH10, revealed that several of the
the bacterial clones, but expression of p51 was induced
substitutions leading to amino acids found in the group
with isopropyl b-D-thiogalactoside. Several E. coli strains
O enzyme (Glu-169 r Asp, Lys-172 r Arg, Asp-177 r
were tested for expression of both subunits. Although ex-
Glu, Ile-178 r Leu, Ile-195 r Leu, Gln-197 r Glu, Thr-
pression levels of p66 and p51 were similar in DH5a and
200 r Lys, and Ile-202 r Val) did not have a major effect
in several TOPP strains, the highest purity of the purified
on the DNA polymerase specific activity of the RT (Chao
heterodimeric RT was obtained with TOPP1 for p66 and
et al., 1995).
DH5a for p51. In this case, enzymes were at least 90%
Enzymological characterization of the group O HIV-1
pure, as judged by SDS–PAGE. The overall yield of the
RT was carried out after expression and purification of
process was 0.05–0.1 mg of protein per liter of bacterial
the enzyme derived from the ESP1 isolate. The results
culture.
indicate that group O and group M enzymes are very
similar in terms of DNA polymerization kinetics, and sen-Kinetic properties and inhibitor sensitivity of
sitivity to nucleotide analogue inhibitors of RT. For exam-recombinant group O HIV-1 RT
ple, the Ki for ddTTP and AZTTP ranged from 2.9 to 14.0
nM for both enzymes, with differences of less than three-The specific DNA polymerase activity of the purified
group O HIV-1 RT was similar to that obtained with puri- fold for the same inhibitor. These values are similar to
those reported for the group M subtype B strain, HXB2fied RT of the BH10 isolate (data not shown;
MartıB n-HernaB ndez et al., 1996). The RNase H-specific (Martin et al., 1993; Gu et al., 1994). The largest differ-
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TABLE 3
Kinetic Parameters for dTTP Incorporation and Estimated Kd Values for Poly(rA)roligo(dT)20 of HIV-1 Group O
and Group M Reverse Transcriptases a
Enzymes kcat (s01) Km (mM ) kcat /Km (mM01rs01) Kd (nM )
Group O (ESP1) 0.29 { 0.10 4.0 { 1.6 75.2 { 16.0 1.4 { 0.2
Group M (BH10) b 0.47 { 0.16 6.7 { 1.7 70.1 { 10.8 7.3 { 1.8
a Poly(rA)roligo(dT)20 was used as substrate. The template/primer nucleotide ratio was 10:1 (approximate molar ratio 1:2.5). Data shown are the
mean values { standard deviation, obtained from a nonlinear least squares fit of the kinetics data to the Michaelis–Menten equation. Each of the
experiments was performed independently at least three times. The kcat values are given assuming that 50% of the enzyme was active as determined
by active site titration (Martin-Herna´ndez et al., 1996).
b Reported data for this enzyme were taken from Martı´n-Herna´ndez et al. (1996).
ences between the RT of HIV-1 group M and group O 1996, Domingo et al., 1997). This substitution has not
been found in other RTs of HIV-1, HIV-2, or SIV, but itwere observed with regard to inhibition by nonnucleo-
side RT inhibitors such as nevirapine or loviride. The IC50 is present in HIV-1 group O isolates ESP1 and ANT70.
Analysis of the surface area of the RT in contact withfor loviride was in the micromolar range for all tested
substrates using the RT of the BH10 isolate, in agreement nevirapine or the a-anilinophenylacetamide derivative R
95845 (a loviride enantiomer) based on their reportedwith the data of Pauwels et al. (1993) using an enzyme
of a closely related strain of HIV-1. Similar results were crystal structures (Kohlstaedt et al., 1992; Ding et al.,
1995), revealed that Tyr-181 makes close contact withobtained with nevirapine. Its IC50 (0.16 mM), determined
in the presence of poly(rC)roligo(dG)12 – 18 and dGTP, us- both inhibitors (Erickson and Burt, 1996).
Two additional residues found in group M HIV-1 RTing the recombinant RT of the BH10 isolate, falls within
the same range of other reported values for the same (Val-179 and Lys-102) which are located within van der
Waals contact distance with nevirapine and a-anilino-substrates and closely related RTs (Merluzzi et al., 1990;
Byrnes et al., 1993; Ahgren et al., 1995; Zhang et al., phenylacetamide derivative R 95845 are also substituted
in the RT of the ESP1 isolate. The contribution of Lys-1995). On the other hand, nevirapine and loviride had no
effect on the RT of HIV-1 group O (IC50  200 mM). These 102 to the contact surface area is very small, and to
our knowledge, amino acid replacements at this positionresults are consistent with previous observations on the
phenotypic resistance of HIV-1 group O isolates grown have not been associated with the acquisition of resis-
tance to nonnucleoside RT inhibitors. However, the con-in the presence of nonnucleoside RT inhibitors (Des-
camps et al., 1995). Three residues of HIV-1 group O RT tribution of Val-179 is significant, particularly in com-
plexes between RT and the a-anilinophenylacetamide(Cys-181, Glu-179, and Gly-98) are also found in group
M (subtype B) strains resistant to nonnucleoside RT in- derivative R 95845 (Ding et al., 1995; Erickson and Burt,
1996). Group O HIV-1 isolates including ESP1 have Gluhibitors (reviewed in Mellors et al., 1996; and Domingo
et al., 1997). The substitution of Tyr-181 by Cys has been at position 179, instead of Val as occurs in group M
strains. In the RTs of HIV-2 and SIV, Ile, Leu, Thr, Asp,shown to confer high-level resistance to loviride (a-anili-
nophenylacetamide derivative R 89439), nevirapine, and and Glu are also found at this position, while in group
M HIV-1, the Val-179 r Glu substitution has been re-practically all tested nonnucleoside RT inhibitors
(Pauwels et al., 1993; Richman et al., 1994; Mellors et al., ported to confer some resistance to pyridinone L-
697,661, and TIBO R82913 (Byrnes et al., 1993). Site-
directed mutagenesis experiments revealed that in these
TABLE 4 viruses, the similar substitution of Val-179 by Asp renders
an enzyme with a wild-type DNA polymerase activityInhibition of HIV-1 Group O and Group M Reverse Transcriptases
by Dideoxynucleotide Triphosphates a (Boyer et al., 1993). Furthermore, this amino acid change
confers resistance to several groups of nonnucleoside
Ki (nM ) inhibitors of RT (e.g., nevirapine, TIBO compounds, delav-
irdine, pyridinones, HEPT derivatives, quinoxaline deriva-Enzymes ddTTP AZTTP
tives, and several thiocarboxyanilides) (Mellors et al.,
Group O (ESP1) 5.9 { 0.4 2.9 { 1.6 1996, and references therein).
Group M (BH10) 14.0 { 2.1 6.3 { 3.2 In subtype B HIV-1 strains, the substitution of Ala-98
by Gly has been shown to confer low-level resistancea Poly(rA)roligo(dT)20 was used as substrate. The template/primer to pyridinones, nevirapine, TIBO derivative R82913, andnucleotide ratio was 10:1 (approximate molar ratio 1:2.5). Data shown
several thiocarboxyanilides (Byrnes et al., 1993; Buckheitare the mean values{ standard deviation of at least three independent
experiments. et al., 1995). Ala-98 is found in all group M strains of HIV-
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TABLE 5
Inhibition of HIV-1 Group O and Group M Reverse Transcriptases by Nevirapine and Loviride a
IC50 (mM )
Enzymes Template/primer Nevirapine Loviride
Group O (ESP1) poly(rA)roligo(dT)20 200 200
poly(rA)roligo(dT)12–18 200 200
poly(rC)roligo(dG)12–18 200 200
poly(dC)roligo(dG)12–18 200 200
Group M (BH10) poly(rA)roligo(dT)20 2.4 { 0.4 4.7 { 0.7
poly(rA)roligo(dT)12–18 1.2 { 0.1 8.2 { 1.4
poly(rC)roligo(dG)12–18 0.16 { 0.02 0.5 { 0.2
poly(dC)roligo(dG)12–18 1.2 { 0.2 6.0 { 1.2
a The template/primer nucleotide ratio was 10:1 when poly(rA)roligo(dT)20 was used as substrate, 1:1 for poly(rA)roligo(dT)12–18 and poly(rC)roli-
go(dG)12–18 , and 2:1 for poly(dC)roligo(dG)12–18 . Tritium-labeled dTTP and dGTP were used as substrates at a 2 mM concentration. Reported data
(mean value { standard deviation) were obtained using duplicate determinations with saturating levels of template-primer, at seven or eight different
inhibitor concentrations. Each experiment was done at least twice for each enzyme and template-primer.
1 as well as in most of HIV-2 and SIV isolates. However, drugs must be able to cope with an immense diversity
of viral genotypes which may prevail in different humanGly-98 occurs in all the RT sequences of group O viruses
and has been observed in an SIV isolate from African populations. It is also possible that different strains ac-
quire resistance to inhibitors through different patternsSykes’ monkeys (Hirsch et al., 1993). In summary, the
observed amino acid substitutions at the nonnucleoside of amino acid substitutions. From this point of view, the
purified recombinant group O HIV-1 RT is expected toRT inhibitor binding site of group O HIV-1 RT can explain
the differences in inhibitor sensitivity between group M be a valuable tool to address those questions.
and group O RTs.
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